Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 12Gastrointestinal 7Gynecologic 4Thoracic 3Dermatologic 2CNS 2Breast 2Sarcoma 1Lymphoid 1Head & Neck 1Genitourinary 1

Conditions

Sarcoma 2Recurrence 2Osteosarcoma 2Sarcoma, Kaposi 1Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Glioma 1GIST 1Central Nervous System Neoplasms 1Bone Neoplasms 1

Interventions

Cyclophosphamide 17pembrolizumab 12Doxorubicin 10fludarabine 7Irinotecan 7Blood Specimen Collection 7Temozolomide 6Gemcitabine 6Etoposide 6Radiotherapy 5Ifosfamide 5Carboplatin 5Albumin-Bound Paclitaxel 5tecogalan 4cemiplimab 4Vincristine 4Trabectedin 4Paclitaxel 4Nivolumab 4Filgrastim 4Drug Therapy 4Dexamethasone 4Bevacizumab 4pazopanib 3olaparib 3nilotinib 3dostarlimab 3aflibercept 3Therapeutics 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × lenvatinib × Sarcoma × Clear all
NCT02432274 2023-07-11

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Eisai Inc.

Phase 1/2 Completed
117 enrolled 32 charts
Sarcoma

Neoplasms, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡